Learn more about whether Lyra Therapeutics, Inc. is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how (LYRA) grades on certain investment factors and determine whether it meets your investment needs.

Latest Lyra Therapeutics, Inc. Stock News

As of December 12, 2025, Lyra Therapeutics, Inc. had a $6.5 million market capitalization, putting it in the 3rd percentile of companies in the Pharmaceuticals industry.

Lyra Therapeutics, Inc. does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Lyra Therapeutics, Inc.’s trailing 12-month revenue is $0.6 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-1.500 per share for the current fiscal year. Lyra Therapeutics, Inc. does not currently pay a dividend.



Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Lyra Therapeutics, Inc. Stock

Before you choose to buy, sell or hold Lyra Therapeutics, Inc. stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (LYRA) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Lyra Therapeutics, Inc.’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Lyra Therapeutics, Inc. Stock Growth Grade

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the Growth Score and assign it a letter grade, the percentile ranks for each of the three individual components‐consistency of annual sales growth, five‐year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered Very Weak, while those in the top 20% receive A grades, which are considered Very Strong.

Lyra Therapeutics, Inc. does not have a meaningful Growth Score.

Don’t Miss Your Free Report — Sign Up Here!

Lyra Therapeutics, Inc. Stock Quality Grade

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Grade is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Lyra Therapeutics, Inc. has a Quality Score of 1, which is Very Weak.

Lyra Therapeutics, Inc. Stock Earnings Estimate Revisions Grade

The Earnings Estimate Revisions Score considers the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. The Earnings Estimate Revisions Score is based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Lyra Therapeutics, Inc. has an Earnings Estimate Revisions Score of 69, which is Positive.

Other Lyra Therapeutics, Inc. Stock Grades

In addition to Growth, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Momentum.

The Momentum Grade helps uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a stock. Further, by joining A+ Investor you can see whether Lyra Therapeutics, Inc.’s stock passes any of our 60+ stock screens that have outperformed the market since their creation.

Should I Buy Lyra Therapeutics, Inc. Stock?

Overall, Lyra Therapeutics, Inc. stock has a Growth Grade of NA, Quality Grade of F, Earnings Estimate Revisions Grade of B.

Whether or not you should buy Lyra Therapeutics, Inc. stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure these out and identify which investments align with what works best for you.

Lastly, it’s important to evaluate a stock by comparing it against others in the same industry. Review the table below to see how Lyra Therapeutics, Inc. stock stands up against its competitors. Click into any of the below tickers to see their stock grades for value, momentum, quality and EPS revisions.

Lyra Therapeutics, Inc. (LYRA) Competitors

Companies similar to Lyra Therapeutics, Inc. in the Pharmaceuticals industry.

Company name	Ticker	Market Cap
Jaguar Health, Inc.	JAGX	$5.04Mil
ProPhase Labs, Inc.	PRPH	$5.30Mil
Sonoma Pharmaceuticals, Inc.	SNOA	$6.11Mil
InMed Pharmaceuticals Inc.	INM	$4.01Mil
Purple Biotech Ltd	PPBT	$1.99Mil

Lyra Therapeutics, Inc. Stock: Bottom Line

You can use the information about how Lyra Therapeutics, Inc. is graded to determine if you should invest in this stock. However, you should decide whether Lyra Therapeutics, Inc.’s stock is a buy, sell or hold based on a combination of grades, metrics, ratios and U.S. Securities and Exchange Commission (SEC) reports.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets—without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

So, if you’re still on the fence about whether Lyra Therapeutics, Inc. is a buy, sell or hold, you can utilize AAII’s expansive and robust screening tools like A+ Investor to help with your decision.

A+ Investor adds to its qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions, find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.